<DOC>
	<DOCNO>NCT00176137</DOCNO>
	<brief_summary>Patients randomize ( arm A ) 3 cycle cisplatin/etoposide , follow hyperfractionated radiotherapy ( hfRT ) concurrent carboplatin vindesine surgery , R1/2-resection , additional hfRT versus ( arm B ) 3 cycle cisplatin/etoposide , follow surgery RT . The primary endpoint progression free survival ( PFS ) . With 500 patient evaluable improvement median PFS 10 14 month could detect .</brief_summary>
	<brief_title>Preoperative Twice Daily Chemoradiation Addition Chemotherapy Prior Surgery Stage III Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Patients randomize ( arm A ) 3 cycle cisplatin 55 mg/m2 ( 1 + 4 ) /etoposide 100 mg/m2 ( 1-4 ) , follow hyperfractionated radiotherapy ( hfRT ; 45 Gy , 2x1.5 Gy/d ) concurrent carboplatin ( 100 mg/m2 ) vindesine ( 3 mg ) ( 1 , 8 , 15 ) , surgery , R1/2-resection , additional hfRT ( 24 Gy ; 2x1.5 Gy/d ) versus ( arm B ) 3 cycle cisplatin 55 mg/m2 ( 1 + 4 ) /etoposide 100 mg/m2 ( 1-4 ) , follow surgery RT ( 1.8 Gy/d ) 54 Gy , R1/2-resection , 68.4 Gy . The primary endpoint progression free survival ( PFS ) . With 500 patient evaluable improvement median PFS 10 14 month could detect . ( University MÃ¼nster lead sponsor ; trial implement clinicaltrials.gov principal investigator move University Heidelberg account announce )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>nonsmall cell lung cancer proven histology stage IIIA / stage IIIB mediastinoscopy performance score ECOG 0,1 predict postoperative FEV 1 &gt; 1.0 l small cell lung cancer cardiac disability ( NYHA III/IV ) prior radio chemotherapy pregnancy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>multimodality treatment</keyword>
</DOC>